Challenging our past paradigm in the management of epilepsy.
Trial designs of antiepileptic drugs have been reviewed. Add-on trials that were used to obtain marketing approval for many of the new antiepileptic drugs provide useful information but have definite limitations. The new monotherapy trial designs offer greater promise both in the provision of safety and efficacy information for registration purposes as well as the clinical use of these new agents to physicians.